Form 4: Acadia Pharmaceuticals Executive Acquires Stock Options and Restricted Stock Units

Elizabeth H.Z. Thompson, EVP, Head of Research & Development at Acadia Pharmaceuticals, reports acquisition of stock options and restricted stock units.

Summary

• On March 24, 2025, Elizabeth H.Z. Thompson, EVP, Head of Research & Development at Acadia Pharmaceuticals, acquired 91,395 stock options with an exercise price of $17.23.
• These options vest 25% on March 24, 2026, and the remainder in 36 equal monthly installments.
• Thompson also acquired 26,861 restricted stock units (RSUs), each representing a contingent right to receive one share of Acadia Pharmaceuticals' common stock.
• These RSUs vest in four equal annual installments beginning March 24, 2026.
• Following these transactions, Thompson directly owns 91,395 stock options and 26,861 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard Form 4 filing. The acquisition of stock options and RSUs by an executive is generally a positive sign, but it's a routine occurrence.

Positives

• The acquisition of stock options and restricted stock units by a key executive could be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both the stock options and RSUs incentivize long-term commitment from the executive.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company executives and their confidence in the company's prospects.

Stakeholder Impact

• The acquisition of stock options and RSUs by a key executive could positively influence shareholder sentiment, reflecting confidence in the company's future.

Key Dates

Keywords

Acadia Pharmaceuticals, stock options, restricted stock units, insider trading, Form 4, executive compensation, Elizabeth H.Z. Thompson